company background image
NB11 logo

Vaxart DB:NB11 Stock Report

Last Price

€0.57

Market Cap

€130.9m

7D

-0.2%

1Y

-11.4%

Updated

22 Nov, 2024

Data

Company Financials +

NB11 Stock Overview

A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. More details

NB11 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Vaxart, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vaxart
Historical stock prices
Current Share PriceUS$0.57
52 Week HighUS$1.33
52 Week LowUS$0.44
Beta0.70
11 Month Change-18.36%
3 Month Change-22.19%
1 Year Change-11.40%
33 Year Change-91.36%
5 Year Change148.48%
Change since IPO-17.17%

Recent News & Updates

Recent updates

Shareholder Returns

NB11DE BiotechsDE Market
7D-0.2%-0.7%-0.02%
1Y-11.4%-17.2%8.2%

Return vs Industry: NB11 exceeded the German Biotechs industry which returned -17.5% over the past year.

Return vs Market: NB11 underperformed the German Market which returned 7.4% over the past year.

Price Volatility

Is NB11's price volatile compared to industry and market?
NB11 volatility
NB11 Average Weekly Movement16.6%
Biotechs Industry Average Movement6.4%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.9%
10% least volatile stocks in DE Market2.4%

Stable Share Price: NB11's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: NB11's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a109Steven Lovaxart.com

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral.

Vaxart, Inc. Fundamentals Summary

How do Vaxart's earnings and revenue compare to its market cap?
NB11 fundamental statistics
Market cap€130.89m
Earnings (TTM)-€69.47m
Revenue (TTM)€16.09m

8.1x

P/S Ratio

-1.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NB11 income statement (TTM)
RevenueUS$16.76m
Cost of RevenueUS$68.14m
Gross Profit-US$51.38m
Other ExpensesUS$20.96m
Earnings-US$72.34m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.32
Gross Margin-306.58%
Net Profit Margin-431.61%
Debt/Equity Ratio7.1%

How did NB11 perform over the long term?

See historical performance and comparison